learn Mesotherapy
technique to inject very small amounts of beneficial chemicals into the scalp
Search
forLearn
5 / 801 resultslearn copper bisglycinate
learn methylsulfonylmethane
learn Liposomal Vitamin E
learn lodine
Research
5 / 506 results
research FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery
The study introduces a finite element analysis (FEA)-guided co-design framework for developing separable bubble microneedles (BMNs) that optimize geometry and cavity parameters for controlled tip separation and robust insertion. The research demonstrated that minoxidil sulfate-loaded BMNs (MXS-BMNs) and insulin-loaded BMNs (INS-BMNs) achieved effective transdermal and sublingual delivery, respectively. MXS-BMNs showed a sevenfold increase in minoxidil permeation compared to topical gel and accelerated hair regrowth in mice, while INS-BMNs provided rapid glucose reduction in diabetic rats. The FEA predictions closely matched experimental results, confirming the framework's efficacy in reducing empirical iteration and expediting BMN development for rapid drug delivery.
research FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery
The study introduces a finite element analysis (FEA)-guided co-design framework for developing separable bubble microneedles (BMNs) that optimize geometry and cavity parameters for controlled tip separation and robust insertion. The research demonstrated that minoxidil sulfate-loaded BMNs (MXS-BMNs) and insulin-loaded BMNs (INS-BMNs) achieved effective transdermal and sublingual delivery, respectively, with separation forces closely matching FEA predictions and axial strengths surpassing skin and mucosa penetration thresholds. In vivo tests showed MXS-BMNs significantly enhanced hair regrowth in mice, while INS-BMNs effectively lowered glucose levels in diabetic rats. This approach reduces empirical iteration, facilitating the rapid development of efficient microneedle systems for drug delivery.
research Alopecias in humans: biology, pathomechanisms and emerging therapies
New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Drug Delivery Applications of Three-Dimensional Printed (3DP) Mesoporous Scaffolds
3D-printed mesoporous scaffolds show promise for personalized drug delivery with controlled release.
Community Join
5 / 108 resultscommunity Any experiences with/thoughts on Zeuss sublinguals?
Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.
community For sublingual minoxidil users and topical minoxidil drinkers : You should STOP spraying topical minoxidil to your mouth NOW. You should consider stopping using a drop of it and mixing it with some other substance too, as you may mess up the dosage
Spraying or drinking topical minoxidil is dangerous and less effective than oral minoxidil. Proper oral minoxidil, like Loniten®, is recommended for safety and effectiveness.
community [M31] 2+ years progress on Oral Dutasteride and Sublingual Minoxidil
A user shared their 2+ years progress on Oral Dutasteride and Sublingual Minoxidil for hair loss. Another user asked about the form of Minoxidil used sublingually.
community Sublingual Minoxidil - Cure to Hairloss?
The conversation discusses the potential benefits of sublingual minoxidil for hair loss treatment. It suggests that sublingual minoxidil, which bypasses the liver, may have fewer side effects, greater bioavailability, and could be more effective than oral minoxidil.
community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.